Phosphate: An old bone molecule but new cardiovascular risk factor

British Journal of Clinical Pharmacology

Volumn 77, Issue 1, 2014, Pages 39-54

  Shobeiri, Navid ^a   Adams, Michael A ^a   Holden, Rachel M ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

cardiovascular disease; chronic kidney disease; hyperphosphataemia; phosphate; SLC20 (PiT1 and 2); vascular calcification

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CINACALCET; FARNOQUINONE; LANTHANUM CARBONATE; PHOSPHATE; PHOSPHATE TRANSPORTER; PLACEBO; PYROPHOSPHATE; TRANSCRIPTION FACTOR PIT 1; TRANSCRIPTION FACTOR PIT 2; UNCLASSIFIED DRUG; VITAMIN D; CALCIMIMETIC AGENT; CHELATING AGENT;

ARTICLE; BLOOD VESSEL CALCIFICATION; BONE REMODELING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; HORMONAL REGULATION; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; NONHUMAN; OSSIFICATION; OSTEOBLAST; PARATHYROID GLAND; PHOSPHATE BALANCE; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; ANIMAL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; CYTOLOGY; HOMEOSTASIS; METABOLISM; OSTEOCLAST; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ANIMALS; BONE REMODELING; CALCIMIMETIC AGENTS; CARDIOVASCULAR DISEASES; CHELATING AGENTS; DIPHOSPHONATES; HOMEOSTASIS; HUMANS; HYPERPHOSPHATEMIA; OSTEOCLASTS; PHOSPHATE TRANSPORT PROTEINS; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR CALCIFICATION; VITAMIN D;

EID: 84881167256     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12117     Document Type: Article

References (174)

1. Hansen NM, Felix R, Bisaz S, Fleisch H,. Aggregation of hydroxyapatite crystals. Biochim Biophys Acta 1976; 451: 549-559.
2. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H,. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348: 1656-1663.
3. Hruska K, Mathew S, Lund R, Qiu P, Pratt R,. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74: 148-157.
4. Knochel JP,. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med 1977; 137: 203-220.
5. Prié D, Beck L, Friedlander G, Silve C,. Sodium-phosphate cotransporters, nephrolithiasis and bone demineralization. Curr Opin Nephrol Hypertens 2004; 13: 675-681.
6. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G,. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
7. Galetta F, Cupisti A, Franzoni F, Femia FR, Rossi M, Barsotti G, Santoro G,. Left ventricular function and calcium phosphate plasma levels in uraemic patients. J Intern Med 2005; 258: 378-384.
8. Bellasi A, Mandreoli M, Baldrati L, Corradini M, Di Nicolò P, Malmusi G, Santoro A,. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 2011; 6: 883-891.
9. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL,. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
10. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM,. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
11. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA,. Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study. Kidney Blood Press Res 2009; 32: 37-44.
12. Foley RN,. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol. 2009; 4: 1136-1139.
13. Kornberg A,. The enzymatic replication of DNA. CRC Crit Rev Biochem 1979; 7: 23-43.
14. Rothfield L, Finkelstein A,. Membrane biochemistry. Annu Rev Biochem 2003; 37: 463-495.
15. Carpenter CL, Cantley LC,. Phosphoinositide kinases. Curr Opin Cell Biol 1996; 8: 153-158.
16. Krebs EG, Beavo JA,. Phosphorylation-dephosphorylation of enzymes. Annu Rev Biochem 1979; 48: 923-959.
17. Hubbard SR, Till JH,. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69: 373-398.
18. Uribarri J, Calvo MS,. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 1990; 16: 186-188.
19. Gutiérrez OM, Anderson C, Isakova T, Scialla J, Negrea L, Anderson AH, Bellovich K, Chen J, Robinson N, Ojo A, Lash J, Feldman HI, Wolf M,. Low socioeconomic status associates with higher serum phosphate irrespective of race. J Am Soc Nephrol 2010; 21: 1953-1960.
20. Magagnin S,. Expression cloning of human and rat renal cortex Na/Pi cotransport. Proc Natl Acad Sci U S A 1993; 90: 5979-5983.
21. Kavanaugh MP, Miller DG, Zhang W, Law W, Kozak SL, Kabat D, Miller D,. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci U S A 1994; 91: 7071-7075.
22. Kavanaugh MP, Kabat D,. Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kidney Int 1996; 49: 959-963.
23. +-Pi cotransporters. Am J Physiol Renal Physiol 1999; 276: F644-649.
24. Virkki LV, Biber J, Murer H, Forster IC,. Phosphate transporters: a tale of two solute carrier families. Am J Physiol Renal Physiol 2007; 293: F643-654.
25. Hattenhauer O, Traebert M, Murer H, Biber J,. Regulation of small intestinal Na-Pi type IIb cotransporter by dietary phosphate intake. Am J Physiol Gastrointest Liver Physiol 1999; 277: G756-762.
26. Ravera S, Virkki LV, Murer H, Forster IC,. Deciphering PiT transport kinetics and substrate specificity using electrophysiology and flux measurements. Am J Physiol Cell Physiol 2007; 293: C606-620.
27. Rizzoli R, Fleisch H, Bonjour JP,. Role of 1,25-dihydroxyvitamin D3 on intestinal phosphate absorption in rats with a normal vitamin D supply. J Clin Invest 1977; 60: 639-647.
28. Liu S, Guo R, Simpson LG, Xiao Z-S, Burnham CE, Quarles LD,. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003; 278: 37419-37426.
29. Mirams M, Robinson BG, Mason RS, Nelson AE,. Bone as a source of FGF23: regulation by phosphate? Bone 2004; 35: 1192-1199.
30. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ,. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60: 2079-2086.
31. Francis F, Hennig S, Korn B, Reinhardt R, De Jong P, Poustka A, Lehrach H, Rowe PS, Goulding JN, Summerfield T, Mountford R, Read AP, Popowska E, Pronicka E, Davies KE, O'Riordan JLH, Econs MJ, Nesbitt T, Drezner MK, Oudet C, Pannetier S, Hanauer A, Strom TM, Meindl A, Lorenz B, Cagnoli B, Mohnike KL, Murken J, Meitinger T,. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995; 11: 130-136.
32. Zhang R, Lu Y, Ye L, Yuan B, Yu S, Qin C, Xie Y, Gao T, Drezner MK, Bonewald LF, Feng JQ,. Unique roles of phosphorus in endochondral bone formation and osteocyte maturation. J Bone Miner Res 2011; 26: 1047-1056.
33. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Jüppner H, Jonsson KB,. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004; 145: 3087-3094.
34. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T,. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314: 409-414.
35. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD,. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007; 18: 2116-2124.
36. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T,. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774.
37. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu M-C, Moe OW, Kuro-o M,. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281: 6120-6123.
38. Farrow EG, Davis SI, Summers LJ, White KE,. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 2009; 20: 955-960.
39. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T,. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
40. Perwad F, Zhang MYH, Tenenhouse HS, Portale AA,. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293: F1577-1583.
41. Petkovich M, Jones G,. CYP24A1 and kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 337-344.
42. Medici D, Razzaque MS, DeLuca S, Rector TL, Hou B, Kang K, Goetz R, Mohammadi M, Kuro OM, Olsen BR, Lanske B,. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol 2008; 182: 459-465.
43. Bouillon R,. Vitamin D: from photosynthesis, metabolism, and action to clinical applications. In: Endocrinology eds, DeGroot LJ, Jameson JL,. Philadelphia, PA: W.B. Saunders 2001; 1009-1028.
44. Bergwitz C, Jüppner H,. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010; 61: 91-104.
45. Keusch I, Traebert M, Lötscher M, Kaissling B, Murer H, Biber J,. Parathyroid hormone and dietary phosphate provoke a lysosomal routing of the proximal tubular Na/Pi-cotransporter type II. Kidney Int 1998; 54: 1224-1232.
46. Pfister MF,. Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. Proc Natl Acad Sci U S A 1998; 95: 1909-1914.
47. Dunlay R, Hruska K,. PTH receptor coupling to phospholipase C is an alternate pathway of signal transduction in bone and kidney. Am J Physiol Renal Physiol 1990; 258: F223-231.
48. Friedman PA,. Parathyroid hormone stimulation of calcium transport is mediated by dual signaling mechanisms involving protein kinase A and protein kinase C. Endocrinology 1996; 137: 13-20.
49. Mahon MJ, Donowitz M, Yun CC, Segre GV,. Na(+)/H(+) exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling. Nature 2002; 417: 858-861.
50. Beck GR,. Inorganic phosphate as a signaling molecule in osteoblast differentiation. J Cell Biochem 2003; 90: 234-243.
51. Bingham PJ, Raisz LG,. Bone growth in organ culture: effects of phosphate and other nutrients on bone and cartilage. Calcif Tissue Res 1974; 14: 31-48.
52. Bellows CG, Heersche JNM, Aubin JE,. Inorganic phosphate added exogenously or released from β-glycerophosphate initiates mineralization of osteoid nodules in vitro. Bone Miner 1992; 17: 15-29.
53. Ducy P,. Cbfa1: a molecular switch in osteoblast biology. Dev Dyn 2000; 219: 461-471.
54. Beck G,. Inorganic phosphate regulates multiple genes during osteoblast differentiation, including Nrf2. Exp Cell Res 2003; 288: 288-300.
55. Tenenbaum HC, Limeback H, McCulloch CAG, Mamujee H, Sukhu B, Torontali M,. Osteogenic phase-specific co-regulation of collagen synthesis and mineralization by β-glycerophosphate in chick periosteal cultures. Bone 1992; 13: 129-138.
56. Boskey AL, Stiner D, Doty SB, Binderman I, Leboy P,. Studies of mineralization in tissue culture: optimal conditions for cartilage calcification. Bone Miner 1992; 16: 11-36.
57. Fratzl-Zelman N, Fratzl P, Hörandner H, Grabner B, Varga F, Ellinger A, Klaushofer K,. Matrix mineralization in MC3T3-E1 cell cultures initiated by β-glycerophosphate pulse. Bone 1998; 23: 511-520.
58. Anderson HC,. Molecular biology of matrix vesicles. Clin Orthop Relat Res 1995; 314: 266-280.
59. Caverzasio J, Bonjour J,. Characteristics and regulation of Pi transport in osteogenic cells for bone metabolism. Kidney Int 1996; 49: 975-980.
60. Caverzasio J, Montessuit C, Bonjour J-P,. Functional role of Pi transport in osteogenic cells. Physiology. 1996; 11: 119-125.
61. Beck GR, Zerler B, Moran E,. Gene array analysis of osteoblast differentiation. Cell Growth Differ 2001; 12: 61-83.
62. Beck GR, Knecht N,. Osteopontin regulation by inorganic phosphate is ERK1/2-, protein kinase C-, and proteasome-dependent. J Biol Chem 2003; 278: 41921-41929.
63. Erk R, Bozec A, Wagner EF, Julien M, Khoshniat S, Lacreusette A, Wittrant Y, Masson M, Weiss P, Beck L, Magne D, Guicheux J,. Phosphate-dependent regulation of MGP in osteoblasts: role of ERK1/2 and Fra-1. J Bone Miner Res 2009; 24: 1856-1868.
64. Li X, Yang H-Y, Giachelli CM,. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-912.
65. Beck L, Leroy C, Salaün C, Margall-Ducos G, Desdouets C, Friedlander G,. Identification of a novel function of PiT1 critical for cell proliferation and independent of its phosphate transport activity. J Biol Chem 2009; 284: 31363-31374.
66. Cells O, Suzuki A, Ghayor C, Guicheux J, Magne D, Quillard S, Kakita A,. Enhanced expression of the inorganic phosphate transporter Pit-1 is involved in BMP-2-induced matrix mineralization in osteoblast-like cells. J Bone Miner Res 2006; 21: 674-683.
67. Li X, Giachelli CM,. Sodium-dependent phosphate cotransporters and vascular calcification. Curr Opin Nephrol Hypertens 2007; 16: 325-328.
68. Steitz S, Speer MY, Curinga G, Yang H-Y, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM,. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154.
69. Mizobuchi M, Ogata H, Hatamura I, Koiwa F, Saji F, Shiizaki K, Negi S, Kinugasa E, Ooshima A, Koshikawa S, Akizawa T,. Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. Nephrol Dial Transplant 2006; 21: 911-916.
70. El-Abbadi M, Giachelli CM,. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 2007; 14: 54-66.
71. Speer MY, Yang H-Y, Brabb T, Leaf E, Look A, Lin W-L, Frutkin A, Dichek D, Giachelli CM,. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104: 733-741.
72. Li X, Yang H-Y, Giachelli CM,. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008; 199: 271-277.
73. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK,. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
74. Proudfoot D, Skepper JN, Hegyi L, Farzaneh-Far A, Shanahan CM, Weissberg PL,. The role of apoptosis in the initiation of vascular calcification. Z Kardiol 2001; 90: (Suppl 3): 43-46.
75. Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, Rees L, Shanahan CM,. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010; 21: 103-112.
76. Schäfer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege JJ, Müller-esterl W, Schinke T, Jahnen-dechent W, Schafer C, Muller-Esterl W,. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366.
77. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL,. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004; 164: 1199-1209.
78. Mathew S, Davies M, Lund R, Saab G, Hruska KA,. Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease. Eur J Clin Invest 2006; 36: (Suppl 2): 43-50.
79. Spronk HM, Soute BA, Schurgers LJ, Cleutjens JP, Thijssen HH, De Mey JG, Vermeer C,. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun 2001; 289: 485-490.
80. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM,. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993; 92: 1686-1696.
81. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS,. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268.
82. Tatsumi S, Segawa H, Morita K, Haga H, Kouda T, Yamamoto H, Inoue Y, Nii T, Katai K, Taketani Y, Miyamoto KI, Takeda E,. Molecular cloning and hormonal regulation of PiT-1, a sodium-dependent phosphate cotransporter from rat parathyroid glands. Endocrinology 1998; 139: 1692-1699.
83. Abraham K, Brault JJ, Terjung RL,. Phosphate uptake and PiT-1 protein expression in rat skeletal muscle. Am J Physiol Cell Physiol 2004; 287: C73-78.
84. Sugita A, Kawai S, Hayashibara T, Amano A, Ooshima T, Michigami T, Yoshikawa H, Yoneda T,. Cellular ATP synthesis mediated by type III sodium-dependent phosphate transporter Pit-1 is critical to chondrogenesis. J Biol Chem 2011; 286: 3094-3103.
85. Zoidis E, Ghirlanda-Keller C, Gosteli-Peter M, Zapf J, Schmid C,. Regulation of phosphate (Pi) transport and NaPi-III transporter (Pit-1) mRNA in rat osteoblasts. J Endocrinol 2004; 181: 531-540.
86. Jin C, Zoidis E, Ghirlanda C, Schmid C,. Dexamethasone and cyclic AMP regulate sodium phosphate cotransporter (NaPi-IIb and Pit-1) mRNA and phosphate uptake in rat alveolar type II epithelial cells. Lung 2010; 188: 51-61.
87. Mune S, Shibata M, Hatamura I, Saji F, Okada T, Maeda Y, Sakaguchi T, Negi S, Shigematsu T,. Mechanism of phosphate-induced calcification in rat aortic tissue culture: possible involvement of Pit-1 and apoptosis. Clin Exp Nephrol 2009; 13: 571-577.
88. Yoshiko Y, Candeliere GA, Maeda N, Aubin JE,. Osteoblast autonomous Pi regulation via Pit1 plays a role in bone mineralization. Mol Cell Biol 2007; 27: 4465-4474.
89. Salaun C, Gyan E, Rodrigues P, Heard JM,. Pit2 assemblies at the cell surface are modulated by extracellular inorganic phosphate concentration. J Virol 2002; 76: 4304-4311.
90. Festing MH, Speer MY, Yang H-Y, Giachelli CM,. Generation of mouse conditional and null alleles of the type III sodium-dependent phosphate cotransporter PiT-1. Genesis 2009; 47: 858-863.
91. Beck L, Leroy C, Beck-Cormier S, Forand A, Salaün C, Paris N, Bernier A, Ureña-Torres P, Prié D, Ollero M, Coulombel L, Friedlander G,. The phosphate transporter PiT1 (Slc20a1) revealed as a new essential gene for mouse liver development. Lewin A, editor. PLoS ONE 2010; 5: e9148.
92. Shroff RC, Shanahan CM,. The vascular biology of calcification. Semin Dial 2007; 20: 103-109.
93. Villa-Bellosta R, Levi M, Sorribas V,. Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-alpha, and Pi. Pflugers Arch-Eur J Physiol 2009; 458: 1151-1161.
94. Boyle WJ, Simonet WS, Lacey DL,. Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
95. Mozar A, Haren N, Chasseraud M, Louvet L, Mazière C, Wattel A, Mentaverri R, Morlière P, Kamel S, Brazier M, Mazière JC, Massy ZA,. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol 2008; 215: 47-54.
96. Hayashibara T, Hiraga T, Sugita A, Wang L, Hata K, Ooshima T, Yoneda T,. Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions. J Bone Miner Res 2007; 22: 1743-1751.
97. Osako MK, Nakagami H, Koibuchi N, Shimizu H, Nakagami F, Koriyama H, Shimamura M, Miyake T, Rakugi H, Morishita R,. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res 2010; 107: 466-475.
98. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM,. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int 2008; 73: 384-390.
99. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, Cochrane BB, Hunt JR, Ludlam SE, Pettinger MB, Gass M, Margolis KL, Nathan L, Ockene JK, Prentice RL, Robbins J, Stefanick ML,. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356: 2591-2602.
100. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ,. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. Isr J Exp Med 1998; 188: 997-1001.
101. Lacey D, Timms E, Tan H-L, Kelley M, Dunstan C, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle W,. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
102. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G,. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
103. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CAM, Lash JP, Hsu C-Y, Leonard MB, Wolf M,. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
104. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM,. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001; 37: 1267-1276.
105. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H,. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
106. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM,. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
107. McIntyre CW,. The functional cardiovascular consequences of vascular calcification. Semin Dial 2007; 20: 122-128.
108. Shobeiri N, Pang J, Adams MA, Holden RM,. Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences. J Hypertens 2013; 31: 160-168.
109. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M,. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.
110. Faul C, Amaral A, Oskouei B, Hu M-C, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend R, Feldman H, St John Sutton M, Ojo A, Gadegbeku C, Di Marco G, Reuter S, Kentrup D, Tiemann K, Brand M, Hill J, Moe O, Kuro-O M, Kusek J, Keane M, Wolf M,. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
111. Slinin Y, Foley RN, Collins AJ,. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793.
112. Stevens LA,. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779.
113. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK,. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187.
114. Garland J, Holden R, Groome P, Lam M, Nolan R, Morton R, Pickett W,. Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease. Am J Kidney Dis 2008; 52: 849-858.
115. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM,. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701.
116. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F,. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106: 100-105.
117. Gutiérrez O, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M,. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
118. Mirza MAI, Larsson A, Melhus H, Lind L, Larsson TE,. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 546-551.
119. Ferreira A, Frazão JM, Monier-Faugere M-C, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH,. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19: 405-412.
120. Asmus H-G, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, Neumayer H-H, Raggi P, Bommer J,. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005; 20: 1653-1661.
121. Guérin AP, London GM, Marchais SJ, Metivier F,. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021.
122. Dialysis Outcomes and Practice Patterns Study (DOPPS). 2010 DOPPS Annual Report [Internet]. Available at http://www.dopps.org/annualreport/index.htm (last accessed 27 September 2012).
123. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK,. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137.
124. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM,. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
125. Di Iorio B, Bellasi A, Russo D,. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012; 7: 487-493.
126. Barreto DV, Barreto FDEC, De Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RMA, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani MEF,. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC study. Nephron Clin Pract 2008; 110: c273-283.
127. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P,. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
128. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M,. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965.
129. Chertow GM, Burke SK, Raggi P,. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
130. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE,. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-1261.
131. London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, De Vernejoul M-C,. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835.
132. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76: S50-99.
133. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, Ketteler M, Meert N, Maizel J, Nikolov IG, Vanholder R, Lacour B, Drüeke TB, Massy Z,. a. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005; 112: 2875-2882.
134. Cozzolino M,. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 2002; 13: 2299-2308.
135. Shobeiri N, Adams MA, Holden RM, Adams A,. Vascular calcification in animal models of CKD: a review. Am J Nephrol 2010; 31: 471-481.
136. Mathew S, Lund RJ, Strebeck F, Tustison KS, Geurs T, Hruska K,. a. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007; 18: 122-130.
137. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N,. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003; 64: 441-450.
138. Tamagaki K, Yuan Q, Ohkawa H, Imazeki I, Moriguchi Y, Imai N, Sasaki S, Takeda K, Fukagawa M,. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant 2006; 21: 651-659.
139. Davies MR, Lund RJ, Mathew S, Hruska K,. a. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005; 16: 917-928.
140. Damment SJP,. Pharmacology of the phosphate binder, lanthanum carbonate. Ren Fail 2011; 33: 217-224.
141. Damment S, Secker R, Shen V, Lorenzo V, Rodriguez M,. Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure. Nephrol Dial Transplant 2011; 26: 1803-1812.
142. Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, Smith M, Pratt RD, Monier-Faugere M-C,. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008; 70: 284-295.
143. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME,. A multicenter study on the effects of lanthanum carbonate (Fosrenoltm) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63: 73-78.
144. Panizo S, Parisi E, Fernandez E, Valdivielso JM,. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-866.
145. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M,. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307.
146. Koleganova N, Piecha G, Ritz E, Schmitt CP, Gross M-L,. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 2009; 75: 60-71.
147. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB,. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
148. Holden RM, Sanfilippo AS, Hopman WM, Zimmerman D, Garland JS, Morton AR,. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol 2007; 20: 417-422.
149. Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees L,. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008; 19: 1239-1246.
150. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Boitte F, Choukroun G, Fournier A, Massy ZA,. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4: 1128-1135.
151. Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, Gutierrez O, Camargo CA, Melamed M, Norris K, Stampfer MJ, Powe NR, Thadhani R,. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19: 1379-1388.
152. Rybczyñska A, Boblewski K, Lehmann A, Orlewska C, Foks H,. Pharmacological activity of calcimimetic NPS R-568 administered intravenously in rats?: dose dependency. Pharmacol Rep 2006; 52: 533-539.
153. Block GA, Martin KJ, De Francisco ALM, Turner S, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman W, Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
154. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N,. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998; 53: 448-453.
155. Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, Slatopolsky E,. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 2010; 298: F1315-1322.
156. Moe SM, Seifert MF, Chen NX, Sinders RM, Chen X, Duan D, Henley C, Martin D, Gattone VH,. R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant 2009; 24: 2371-2377.
157. Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentaverri R, Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Kamel S, Lacour B, Drüeke TB, Massy ZA,. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis 2009; 205: 55-62.
158. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J,. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327-1339.
159. EVOLVE Trial Investigators, Chertow G, Block G, Correa-Rotter R, Drüeke T, Floege J, Goodman W, Herzog C, Kubo Y, London G, Mahaffey K, Mix T, Moe S, Trotman M, Wheeler D, Parfrey P, Investigators TET. Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. N Engl J Med 2012; 367: 2483-2494.
160. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC,. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990; 85: 456-461.
161. Rodan GA, Fleisch HA,. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97: 2692-2696.
162. Ott SM,. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90: 1897-1899.
163. Tamura K, Suzuki Y, Matsushita M, Fujii H, Miyaura C, Aizawa S, Kogo H,. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol 2007; 558: 159-166.
164. Price PA, Roublick AM, Williamson MK,. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 2006; 70: 1577-1583.
165. Hashiba H, Aizawa S, Tamura K, Shigematsu T, Kogo H,. Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 2004; 8: 241-247.
166. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R-I, Majima K, Aoki T, Nihei H,. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 2004; 44: 680-688.
167. O'Neill WC, Lomashvili KA, Malluche HH, Faugere M-C, Riser BL,. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2011; 79: 512-517.
168. Rennenberg RJMW, De Leeuw PW, Kessels AGH, Schurgers LJ, Vermeer C, Van Engelshoven JMA, Kemerink GJ, Kroon AA,. Calcium scores and matrix Gla protein levels: association with vitamin K status. Eur J Clin Invest 2010; 40: 344-349.
169. Małyszko J, Wołczyński S, Skrzydlewska E, Małyszko JS, Myśliwiec M,. Vitamin K status in relation to bone metabolism in patients with renal failure. Am J Nephrol 2002; 22: 504-508.
170. Holden RM, Booth SL,. Vascular calcification in chronic kidney disease: the role of vitamin K. Nat Clin Pract Nephrol 2007; 3: 522-523.
171. Schurgers LJ, Spronk HMH, Soute BAM, Schiffers PM, Demey JGR, Vermeer C,. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007; 109: 2823-2831.
172. Hruska KA, Mathew S, Saab G,. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105-114.
173. Davies MR,. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003; 14: 1559-1567.
174. Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, Wadhera V, Van Leeuwen FN, Touyz RM,. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 2010; 56: 453-462.